Skip to main content
Premium Trial:

Request an Annual Quote

MGI Tech, SeqOne Collaborate for Genomic Analysis Workflows

NEW YORK – MGI Tech said on Monday that it has partnered with SeqOne to develop and validate end-to-end genomic analysis workflows for human genetics and pathology labs.

Financial terms of the deal were not disclosed.

As part of the collaboration, the companies, in conjunction with Agilent Technologies and an undisclosed pathology reference lab in Spain, will develop an automated, sample-to-report assay for homologous recombination deficiency (HRD) testing, leveraging MGI's DNBSeq-G99 platform, Agilent's library prep reagents and automation systems, and SeqOne's SomaHRD analysis solution.

MGI said it will also make its MegaBolt bioinformatics analysis software compatible with SeqOne's AI-powered variant identification and analysis pipeline. Additionally, the companies plan to validate SeqOne's CE-IVD platform for germline and somatic analysis using MGI's sequencers for routine diagnostics.

"Molecular laboratories globally are exploring how MGI's sequencing and bioinformatics technologies can advance next-generation sequencing research and diagnostics," SeqOne CEO Martin Dubuc said in a statement. "We are eager to integrate SeqOne's CE-IVD Platform with MGI's offerings, enhancing the quality, sensitivity, and precision of bioinformatic analyses."